25 Years of Proton Pump Inhibitors: A Comprehensive Review

Proton pump inhibitors (PPIs) were clinically introduced more than 25 years ago and have since proven to be invaluable, safe, and effective agents for the management of a variety of acid-related disorders. Although all members in this class act in a similar fashion, inhibiting active parietal cell a...

Full description

Saved in:
Bibliographic Details
Published in:Gut and liver Vol. 11; no. 1; pp. 27 - 37
Main Authors: Strand, Daniel S., Kim, Daejin, Peura, David A.
Format: Journal Article
Language:English
Published: Korea (South) Editorial Office of Gut and Liver 15.01.2017
Gastroenterology Council for Gut and Liver
거트앤리버 소화기연관학회협의회
Subjects:
Anti-Bacterial Agents - therapeutic use
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Drug Therapy, Combination
Gastroesophageal Reflux - drug therapy
Half-Life
Helicobacter Infections - drug therapy
Humans
indications
Peptic Ulcer - chemically induced
Peptic Ulcer - drug therapy
Peptic Ulcer - prevention & control
pharmacokinetics
proton pump inhibitors
Proton Pump Inhibitors - pharmacokinetics
Proton Pump Inhibitors - therapeutic use
Review
risk
내과학
Indications
Proton pump inhibitors
Risk
Review
Pharmacokinetics
ISSN:1976-2283, 2005-1212, 2005-1212
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Proton pump inhibitors (PPIs) were clinically introduced more than 25 years ago and have since proven to be invaluable, safe, and effective agents for the management of a variety of acid-related disorders. Although all members in this class act in a similar fashion, inhibiting active parietal cell acid secretion, there are slight differences among PPIs relating to their pharmacokinetic properties, metabolism, and Food and Drug Administration (FDA)-approved clinical indications. Nevertheless, each is effective in managing gastroesophageal reflux disease and uncomplicated or complicated peptic ulcer disease. Despite their overall efficacy, PPIs do have some limitations related to their short plasma half-lives and requirement for meal-associated dosing, which can lead to breakthrough symptoms in some individuals, especially at night. Longer-acting PPIs and technology to prolong conventional PPI activity have been developed to specifically address these limitations and may improve clinical outcomes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
G704-SER000001589.2017.11.1.022
ISSN:1976-2283
2005-1212
2005-1212
DOI:10.5009/gnl15502